Networking site to link cancer docs, pharma

More from the Web-marketing frontier, where portals and blogs are passé: An Arizona entrepreneur is working up a site where cancer doctors and drugmakers can mix and mingle. MedTrust Online is developing a database of medical literature, clinical trial info, treatment options, and the like, hoping to keep oncologists informed of the latest and greatest in their specialty areas. "Patients may not be getting the best options because there is a problem with communication," the company's CEO told the Arizona Republic.

One Texas oncology group has already signed up, and three others are close to doing so. A test site for the Texas practice will be launched later this year. MedTrust won't say how much the service might cost, and how it will avoid running afoul of off-label marketing rules is unclear. But it's the sort of thing we're likely to see more of as traditional marketing channels get blocked or dry up and drugmakers continue looking for effective alternatives.

- see the Pharmalot post
- check out the Arizona Republic article

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.